Chitosan-derivative compounds and methods of controlling microbial populations
Inventors
Baker, Shenda M. • Wiesmann, William P.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.
Core Innovation
The invention relates to oral care methods for controlling microbial activity and microbial populations in an individual by administering functionalized chitosan-arginine compounds and chitosan-derivative compounds. The compounds are soluble at physiologic pH and are administered in a therapeutically effective amount with a therapeutically effective excipient. The compounds are characterized by a degree of functionalization and a degree of deacetylation, with structural and compositional relationships defining the resulting functionalization percentage.
The core approach emphasizes controlling charge and terminal-group composition by selecting functional moieties at the chitosan backbone and by using terminal amines, guanidines, acid-amines, and amino-acid-derived X3 groups, including charged natural amino acids such as lysine, histidine, and aspartic/glutamic acid. Co-derivatives with a second functional moiety Y include iron chelators, antioxidants, and fluorescent or cell growth factors, and the compounds can be provided as salts using anionic counterions Z.
The document also focuses on composition constraints intended to support biological performance, including compounds and preparations that are substantially free of compounds having a molecular weight of less than 5000 Da and substantially free of polyarginine polymers. The related disclosure describes planktonic bactericidal/bacteriostatic effects, inhibition or eradication of biofilm formation, and antiviral inactivation.
Claims Coverage
Two independent claims are identified. Across these independent claims, the inventive features center on oral care administration of soluble functionalized chitosan-arginine or chitosan-derivative preparations with defined functionalization parameters, and on restricting the preparation to be substantially free of low-molecular weight (<5000 Da) compounds and substantially free of polyarginine polymers.
Soluble functionalized chitosan-arginine oral care method with constrained composition
An oral care method comprising administering functionalized chitosan-arginine compounds that are soluble at physiologic pH, in a therapeutically effective amount and in a therapeutically effective excipient, wherein the compounds are between 2% and 50% functionalized.
Exclusion of low-molecular weight material and polyarginine polymers
The method further specifies that the compounds are substantially free of compounds having a molecular weight of less than 5000 Da and substantially free of polyarginine polymers.
Purified chitosan-derivative preparation with defined m and q structural parameters
An oral care method for controlling microbial populations comprising administering a purified preparation comprising a chitosan-derivative compound defined by m, q, s, and p+q+m=1, with the percentage degree of functionalization defined as m/(1-q)×100%; X is selected from the recited options.
Exclusion of low-molecular weight material and polyarginine polymers for the purified preparation
The purified preparation is substantially free of compounds having a molecular weight of less than 5000 Da and substantially free of polyarginine polymers.
Overall, the independent claims cover oral care methods that administer either soluble functionalized chitosan-arginine compounds or purified chitosan-derivative compounds having defined functionalization parameters, while requiring that the administered preparation be substantially free of compounds under 5000 Da and substantially free of polyarginine polymers.
Stated Advantages
Controls microbial activity in an individual.
Controls microbial populations.
Compounds are soluble at physiologic pH.
Prevents biofilm formation.
Inhibits planktonic growth of Gram-negative bacteria.
Inhibits planktonic growth of Gram-positive bacteria.
Documented Applications
Oral care method for controlling microbial activity in an individual.
Oral care method for controlling microbial populations by administering purified chitosan-derivative preparations.
Oral care use for controlling microbial activity or controlling microbial populations in an individual, including preventing biofilm formation and inhibiting planktonic growth of selected Gram-positive or Gram-negative bacteria.
Interested in licensing this patent?